This session highlights the latest innovations in structural and valvular cardiology, featuring novel technologies such as a new self-expandable transcatheter aortic valve for aortic stenosis treatment and a temporary atrioventricular sequential pacing system. It also discusses non-clinical testing methodologies supporting U.S. market approvals, non-invasive ultrasound therapy...

Discover cutting-edge innovations in vascular therapies highlighting novel technologies such as Pulse Intravascular Lithotripsy (IVL) for calcium modification and Amplitude Vascular Systems. The session also presents drug-free restenosis control strategies via CD31 camouflage coating promoting physiological-grade healing, emphasizing emerging solutions aimed at improving vascular intervention outcomes.

This session provides a comprehensive guide to large-bore venous access and vessel closure techniques, emphasizing best practices and the advantages of ultrasound-guided suture mediated vessel closure compared to traditional figure-of-eight suture methods. It also addresses strategies to avoid and manage potential complications encountered during these procedures.

Examine diverse clinical scenarios and management strategies for aortic paravalvular leaks (PVL), including complex percutaneous closures post-TAVI and surgical interventions. This session presents challenging cases demonstrating varied presentations and approaches such as mechanical valve loop utilization, highlighting the complexities and tailored solutions required for successful PVL...

September 29th marks the 25th anniversary of the creation of World Heart Day by the World Heart Federation. This day is dedicated to focusing international attention on cardiovascular disease (CVD), which remains one of the leading causes of mortality worldwide [1,2]. Today, we highlight the women...

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Mirvat Alasnag provides her take on REC-CAGEFREE I, a multicenter, non-inferiority trial presented at the ESC Congress 2024 in London.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...